<DOC>
	<DOCNO>NCT00955682</DOCNO>
	<brief_summary>Subjects previously vaccinate 12 23 month age . This extension study start 24 month vaccination subject vaccinate primary study enrol extension phase . No new subject enrol .</brief_summary>
	<brief_title>Study Evaluate Persistence Antibodies After Vaccination With Meningococcal Vaccine GSK134612</brief_title>
	<detailed_description>This study assess long-term protection offer new meningococcal vaccine 134612 compare Meningitec™ 4 year vaccination toddler . Subjects previously vaccinate 12 23 month age GSK Biologicals ' meningococcal vaccine 134612 Meningitec™ . All subject receive least one dose Priorix-Tetra™ . This extension phase start 24 month vaccination subject vaccinate primary study enrol extension study . No new subject enrol . The subject blood sample take 24 , 36 48 month primary vaccination . At Year 4 subject boost meningococcal vaccine give primary study , i.e . either new meningococcal vaccine GSK 134612 Meningitec™ . Blood sample take 1 12 month booster vaccination .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /guardian ( ) comply requirement protocol enrol study . Written inform consent obtain parent ( ) guardian ( ) subject . Healthy subject establish medical history clinical examination enter study . A male female complete primary study 109670 prim investigational Meningitec™ vaccine . Exclusion criterion persistence study entry ( i.e . Month 24 , 36 48 ) : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede subject 's first visit . History meningococcal disease . Administration meningococcal polysaccharide meningococcal polysaccharide conjugate vaccine outside study 109670 . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history . Administration immunoglobulins and/or blood product within three month precede subject first visit . Concurrently participate another clinical study , within 30 day study entry , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Bleeding disorder , thrombocytopenia , subject anticoagulant therapy . Additional exclusion criterion booster vaccination ( checked Month 48 ) : Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior booster vaccination . History allergic disease reaction likely exacerbate component vaccine . Hypersensitivity vaccine contain diphtheria toxoid nontoxic diphtheria toxin protein and/or tetanus toxoid . History hypersensitivity previous administration Meningitec investigational vaccine study 109670 . Hypersensitivity latex . Planned administration/ administration vaccine foreseen protocol within one month 30 day booster dose . Previous vaccination component vaccine within last month . History neurological disorder seizure ( one episode febrile convulsion constitute exclusion criterion ) . Major congenital defect serious chronic illness . Acute disease time vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Meningococcal vaccine GSK134612</keyword>
</DOC>